Fig. 2From: Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutationsComparison of PFS between EGFR 19 del/ALK and non-EGFR 19del/ALK on EGFR-TKI (21.5 vs 7.25 months, P = 0.007)Back to article page